Adjusted probabilities of survival after diagnosis of CML in intermediate- and high-risk persons receiving hydroxyurea or interferon versus persons receiving an HLA-identical sibling bone marrow transplant (A) at any time after diagnosis or (B) within 1 year of diagnosis.